What this Trial Is About

Researchers are conducting an open-label, multicenter, single-arm observational study to monitor patients with neovascular age-related macular degeneration (nAMD) who are prescribed brolucizumab (Beovu® Injection, Beovu® Prefilled Syringe). The study aims to gather safety information and evaluate the effectiveness of brolucizumab in real-world use following its approved indication. This post-marketing surveillance study collects data over a 12-week period, with additional longer-term data collection planned at 24 and optionally 36 weeks. Participants in this study have already started treatment with brolucizumab before being enrolled, as there is no treatment allocation or randomization. The study is purely observational, focusing on those prescribed brolucizumab according to the approved local product information. No changes to their treatment are made as part of the study. During the study, researchers will monitor participants for adverse events and treatment outcomes, with the primary outcome being the incidence of adverse events observed within the first 12 weeks. Participants will be followed for safety and effectiveness assessments throughout the study duration, including optional longer-term follow-ups up to 36 weeks.

Regulatory Post-Marketing Surveillance Study for Brolucizumab